Anti-Smooth Muscle Antibodies (ASMA)
Autoantibodies directed against cytoskeletal microfilaments, predominantly F-actin (filamentous actin) in smooth muscle and hepatocytes.
Standard vs. Optimal Reference RangesTiter
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<1:20 titer (negative)
General reference distribution across unselected commercial populations.
Negative (<1:20)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Targets hepatocyte canalicular F-actin cytoskeleton, mediating T-cell infiltration, interface hepatitis, and progressive bridging fibrosis.
Differential Diagnosis
Elevated Levels (ASMA High)
- •Type 1 Autoimmune Hepatitis (high titers >1:80 indicate active hepatitis)
- •Primary Biliary Cholangitis overlap
Low Levels (ASMA Low)
- •Viral hepatitis (low transient titers without F-actin specificity)
- •Healthy hepatic baseline
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for ASMA
- Targeted organ system imaging or functional dynamic testing related to autoimmune hepatitis type 1
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Smooth Muscle Antibodies - The New England Journal of Medicine (2021). PMID: 34090124
- [2]ASMA Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Smooth Muscle Antibodies (ASMA) into overall healthspan optimization.